ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients

Mabwell announced Phase Ib/IIa clinical results for its anti-ST2 monoclonal antibody 9MW1911 in patients with chronic obstructive pulmonary disease (COPD). The release provides clinical-update context for the program, but the excerpt does not include efficacy/safety figures or guidance that would clearly signal upside or downside. Overall, this is informational for investors and likely limited near-term impact without the reported data.